Siegfried also announced the following personnel changes: Klaus Stingl, currently head of the company’s Zofingen site, has been appointed as global head of Business Development and Sales Drug Substances, effective Feb. 1, 2024. Martin Kessler, formerly chief transformation officer at Rentschler, will become CEO of Dinamiqs, a Siegfried subsidiary, as of Mar. 1, 2024, while the current CEO Eduard Ayuso will become chief technology officer.

Manja Boerman, formerly president Cell, Gene and Protein Therapy at Catalent, is to join as a new independent board member of Dinamiqs.

In his new role, Stingl becomes member of Siegfried’s extended executive committee. He joined the company in 2016. Prior to Siegfried, Stingl held several senior positions at Evonik. He holds a Ph.D. in organic chemistry from University of Oldenburg, Germany.